Stock A241820 PCL, INC.
Add to a list
To use this feature you must be a member
Log inSign up

PCL, Inc. Stock

Equities

A241820

KR7241820000

Biotechnology & Medical Research

End-of-day quote Korea S.E.
Other stock markets
 06:00:00 2024-06-06 pm EDT 		5-day change 1st Jan Change
1,020 KRW +2.20% Intraday chart for PCL, Inc. +1.59% -71.55%
Jan. 16 PCL, Inc. announced that it has received KRW 9.99999885 billion in funding from Global Emerging Markets CI
2023 PCL, Inc. announced that it has received KRW 9.99999838 billion in funding from Global Emerging Markets CI

Financials

Sales 2022 37.22B 27.21M Sales 2023 8.43B 6.16M Capitalization 185B 135M
Net income 2022 -4.02B -2.94M Net income 2023 -20.32B -14.85M EV / Sales 2022 4.68 x
Net cash position 2022 1.29B 940K Net Debt 2023 7.2B 5.27M EV / Sales 2023 22.8 x
P/E ratio 2022
-39.2 x
P/E ratio 2023
-7.17 x
Employees 35
Yield 2022 *
-
Yield 2023
-
Free-Float 61.53%
More Fundamentals * Assessed data

Chart PCL, Inc.

Dynamic Chart

Latest news about PCL, Inc.

PCL, Inc. announced that it has received KRW 9.99999885 billion in funding from Global Emerging Markets CI
PCL, Inc. announced that it has received KRW 9.99999838 billion in funding from Global Emerging Markets CI
PCL, Inc. announced that it expects to receive KRW 9.99999885 billion in funding from Global Emerging Markets CI
PCL, Inc. announced that it expects to receive KRW 9.99999838 billion in funding from Global Emerging Markets CI
South Korean Stocks Close Lower as Uncertainties Around US Debt Ceiling Deal Remain; PCL Loses 13% MT
PCL to Raise 36 Billion Won via Share Issuance MT
PCL, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
PCL, Inc. announced that it has received KRW 2.999990812 billion in funding from Hyeopsim Co ., Ltd. CI
PCL to Raise 3 Billion Won via Share Issuance; Shares Jump 4% MT
PCL, Inc. announced that it expects to receive KRW 2.999990812 billion in funding from Hyeopsim Co ., Ltd. CI
PCL, Inc. terminated the acquisition of 40.76% stake in mCureX Therapeutics, Inc. from OliX Pharmaceuticals, Inc, Samyang Holdings Corporation, AJU Good Growth Support Fund managed by Aju IB Investment Co., Ltd. and Kiwoom New Hero Fund I managed by Kiwoom Investment Co., Ltd. CI
PCL, Inc. announced that it has received KRW 12.060247575 billion in funding CI
OliX Pharmaceuticals, Inc agreed to acquire 6.63% stake in PCL, Inc. for KRW8.04 billion. CI
PCL, Inc. agreed to acquire unknown minority stake in stake in mCureX Therapeutics, Inc. from OliX Pharmaceuticals, Inc, Samyang Holdings Corporation, AJU Good Growth Support Fund managed by Aju IB Investment Co., Ltd. and Kiwoom New Hero Fund I managed by Kiwoom Investment Co., Ltd. for KRW12.2 billion. CI
PCL, Inc.(KOSDAQ:A241820) dropped from S&P Global BMI Index CI
More news

Quotes and Performance

1 day-0.50%
1 week-0.60%
Current month-0.40%
1 month-15.78%
3 months-9.36%
6 months-75.45%
Current year-72.16%
More quotes

Highs and lows

1 week
981.00
Extreme 981
1 036.00
1 month
981.00
Extreme 981
1 322.00
Current year
981.00
Extreme 981
3 875.00
1 year
981.00
Extreme 981
4 725.00
3 years
981.00
Extreme 981
21 500.00
5 years
981.00
Extreme 981
26 166.67
10 years
981.00
Extreme 981
26 166.67
More quotes

Managers and Directors - PCL, Inc.

Managers TitleAgeSince
So-Yeon Kim CEO
 Chief Executive Officer 53 -
Seung-Ki Hong AUD
 Comptroller/Controller/Auditor 70 -
Members of the board TitleAgeSince
Mahn-Soon Hwang BRD
 Director/Board Member 54 -
Chul-Joon Kim BRD
 Director/Board Member 71 -
So-Yeon Kim CEO
 Chief Executive Officer 53 -
More insiders

Quotes

Date Price Change Volume
24-06-06 1,020 +2.20% 81 458
24-06-05 998 -0.50% 85,569
24-06-04 1,003 +0.30% 78,566
24-06-03 1,000 -0.20% 139,409
24-05-31 1,002 -0.20% 157,066

End-of-day quote Korea S.E., June 04, 2024

More quotes

Company Profile

PCL Inc. is a Korea-based company principally engaged in development and manufacture of vitro diagnostic medical device for immunological diagnosis. The Company’s products include blood bank screening products and quick diagnostic products. And the Company also provides platform services.
Sector
Biotechnology & Medical Research
Calendar
2024-08-12 - Q2 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Sector Bio Diagnostics & Testing

1st Jan change Capi.
PCL, INC. Stock PCL, Inc.
-72.16% 39.5M
EXACT SCIENCES CORPORATION Stock Exact Sciences Corporation
-39.62% 8.24B
GUARDANT HEALTH, INC. Stock Guardant Health, Inc.
+7.28% 3.55B
IOVANCE BIOTHERAPEUTICS, INC. Stock Iovance Biotherapeutics, Inc.
+0.12% 2.28B
BGI GENOMICS CO., LTD. Stock BGI Genomics Co., Ltd.
-21.06% 1.98B
VERACYTE, INC. Stock Veracyte, Inc.
-22.17% 1.64B
MARAVAI LIFESCIENCES HOLDINGS, INC. Stock Maravai LifeSciences Holdings, Inc.
+29.16% 1.12B
CAREDX, INC Stock CareDx, Inc
+28.50% 803M
SEEGENE, INC. Stock Seegene, Inc.
-9.39% 700M
ADAPTIVE BIOTECHNOLOGIES CORPORATION Stock Adaptive Biotechnologies Corporation
-20.20% 575M
Bio Diagnostics & Testing
  1. Stock Market
  2. Equities
  3. A241820 Stock